- Home
- XCUR vs AEON Comparison
XCUR vs AEON Comparison
Compare XCUR & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$3.66
HOLD
Current Price
$1.04
Company Overview
Basic Information| Metric | XCUR | AEON |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6M | 25.2M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | XCUR | AEON |
|---|---|---|
| Price | $3.66 | $1.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | 21.3K | ★ 85.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $500,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.10 | $0.38 |
| 52 Week High | $15.87 | $1.45 |
Technical Indicators
Market Signals| Indicator | XCUR | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 37.86 | 48.19 |
| Support Level | $3.47 | $0.67 |
| Resistance Level | $4.23 | $1.10 |
| Average True Range (ATR) | 0.26 | 0.12 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 19.80 | 33.13 |
Price Performance
Historical Comparison XCUR
AEON
About XCUR Exicure Inc.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.